Form 4: 10x Genomics CEO Sells Shares Under 10b5-1 Plan

Serge Saxonov, CEO of 10x Genomics, has reported the sale of Class A Common Stock valued at over $25 million through a pre-arranged trading plan.

Summary

• Serge Saxonov, Chief Executive Officer and Director of 10x Genomics, Inc. (TXG), has reported the sale of 10x Genomics Class A Common Stock.
• The transactions occurred on June 22, 2026, and were executed under a Rule 10b5-1 trading plan adopted on November 29, 2025.
• A total of 234,732 shares were sold across multiple transactions with weighted average sale prices ranging from $32.75 to $36.24.
• The total value of the reported sales is approximately $25,100,000.
• Following these transactions, Saxonov directly and indirectly beneficially owns a significant number of shares, with some held through various trusts where he serves as trustee.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the significant volume of shares sold by the CEO, despite the sales being conducted under a pre-established trading plan.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, indicating a pre-determined strategy for stock sales that can provide an affirmative defense against insider trading allegations.
• The CEO continues to hold a substantial number of shares, both directly and indirectly, suggesting continued commitment to the company.

Negatives

• Significant sale of shares by the CEO, totaling over $25 million, which could be perceived negatively by the market.
• The sales occurred at prices ranging from $32.75 to $36.24, indicating a downward trend in the average sale price across the reported transactions.

Risks

• Potential for negative market perception due to the CEO's substantial stock sales.
• The Rule 10b5-1 plan implies a pre-determined selling strategy, which might be executed regardless of short-term company performance or market conditions.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, can sometimes create short-term headwinds for a stock, especially when the sales are substantial. However, the existence of the plan itself is a standard practice for executives managing their personal finances while adhering to regulations.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the CEO's significant stock sale as a negative signal, potentially impacting short-term share price. However, the use of a 10b5-1 plan mitigates concerns about insider trading.
• Employees: May be influenced by the CEO's actions, potentially affecting morale or their own investment decisions.
• Management: The CEO's continued role as trustee for shares held in trusts indicates ongoing indirect beneficial ownership and commitment.

Next Steps

• The Reporting Person may continue to execute sales under the Rule 10b5-1 trading plan.
• The company may provide further information regarding the sales upon request from regulatory bodies or security holders.

Key Dates

Recommendation

The filing reports significant stock sales by the CEO under a 10b5-1 plan. While this can be a short-term negative catalyst, the plan itself is a standard practice. The continued indirect beneficial ownership through trusts suggests ongoing commitment. Without further financial or strategic information, a 'hold' recommendation is prudent, awaiting more substantive company performance updates.

Keywords

10x Genomics, TXG, Serge Saxonov, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Beneficial Ownership, Class A Common Stock, CEO